Host immune system (2009 H1N1 influenza antigens)

The target "Host immune system 2009 antigens" refers to the immunological components of the host that respond to the antigens of the 2009 pandemic H1N1 influenza A virus. These antigens primarily include the surface glycoproteins Hemagglutinin (HA) and Neuraminidase (NA), which were derived from a novel triple-reassortant swine-origin virus (NIH, 2009). Hemagglutinin is responsible for viral attachment to host sialic acid receptors and subsequent membrane fusion, making it the primary target for neutralizing antibodies elicited by vaccines (PubMed, 2015). Neuraminidase facilitates the release of progeny virions from infected cells by cleaving sialic acid residues, and it serves as the primary target for antiviral drugs such as oseltamivir and zanamivir (StatPearls, 2023). The host immune system's interaction with these antigens involves both innate recognition and the development of adaptive B-cell and T-cell responses, which are critical for viral clearance and long-term immunity (Nature Reviews Immunology, 2008). Therapeutic strategies targeting this system include the administration of monovalent or polyvalent vaccines to prevent infection and the use of neuraminidase inhibitors to reduce disease severity. Challenges associated with this target include rapid antigenic drift, which necessitates frequent vaccine updates, and the potential for emerging drug resistance (WHO, 2009).

Other names

2009 H1N1 influenza virus antigensSwine flu antigenspH1N1 antigensHemagglutinin (HA)Neuraminidase (NA)A/California/04/2009 antigens

Stimulation of the host immune system to produce neutralizing antibodies against viral antigens and inhibition of viral neuraminidase to prevent viral release.